Innovative Partnership in Advanced Therapies
BBG Advanced Therapies, a forward-thinking branch of BioBridge Global, has teamed up with CELLforCURE, known for its expertise in cell and gene therapy production. This partnership represents a significant leap in the production of Advanced Therapy Medicinal Products (ATMPs), with a focus on enhancing manufacturing capabilities across the Atlantic.
Leveraging Expertise for Global Impact
Through this collaboration, U.S. enterprises can utilize CELLforCURE’s extensive capacities in Europe, allowing for smoother transitions from development to commercialization. In parallel, European organizations can take advantage of BBG Advanced Therapies’ cutting-edge production facilities located in the United States. This dual approach not only boosts production efficiency but also offers a comprehensive contract development and manufacturing organization (CDMO) service network for ATMP innovators.
State-of-the-Art Facilities and Capabilities
BBG Advanced Therapies stands out in the field with its advanced biomanufacturing capabilities. The facility boasts nine cGMP cleanrooms expanding over 558 m² (6,000 sq. ft.) dedicated to cell and tissue processing. What sets BBGAT apart is its holistic approach to support innovators, encompassing everything from leukapheresis and donor management to testing and cryopreservation, all ensuring compliance with FDA, EMA, and PMDA regulations. Additionally, BBGAT operates the first and only mobile leukapheresis center, further enhancing patient access and convenience.
A Focus on Compliance and Quality
The commitment to excellence is evident in BBG Advanced Therapies' unified Quality Management System, striving to meet stringent safety and quality standards throughout the manufacturing process.
In parallel, CELLforCURE showcases its capabilities with a 10,000 m² facility, featuring GMP-certified spaces across seven independent manufacturing lines. This extensive space is equipped with 32,291 sq. ft. of cleanrooms designed for high compliance and safety, essential for the production of CAR-T and immune cell therapies. CELLforCURE’s significant focus on quality assurance, with 90% of processes controlled in-house, ensures that clients receive the highest quality drug products.
A Seamless Global Network for Therapists
The collaboration between BBG Advanced Therapies and CELLforCURE aims to dissolve barriers in ATMP production, culminating in a scalable global network that particularly facilitates multinational clinical trials. By merging expertise from both sides of the Atlantic, developers are empowered to expedite their projects effectively, enhancing patient accessibility to revolutionary treatments.
About BBG Advanced Therapies
As an integral part of BioBridge Global, BBG Advanced Therapies specializes in facilitating the advancement of cell and gene therapies. Their all-inclusive custom solutions range from the collection and processing of starting materials all the way through clinical trial support and biomanufacturing services. For those seeking innovative therapeutic solutions, BBG Advanced Therapies is a key player in the biomanufacturing sector.
About BioBridge Global
BioBridge Global serves as a nonprofit healthcare services organization with a rich history in enhancing lives through its diverse services, which include blood resource management and cellular therapy. With a commitment to regenerative medicine, BioBridge Global provides essential testing and biomanufacturing support, promoting significant advancements in health and patient care.
About CELLforCURE
Dedicated to transforming ATMP production, CELLforCURE SAS specializes in ensuing seamless production from development stages to commercialization. Their advanced facilities reflect their commitment to excellence in cell therapy manufacturing, allowing them to deliver high-quality solutions throughout the entire production process.
About SEQENS
SEQENS stands as a leader in health and personal care solutions, promoting innovation and sustainability through its extensive network of manufacturing sites and R&D centers worldwide. With a workforce dedicated to the production of high-grade pharmaceutical ingredients, SEQENS’s commitment to quality is apparent in every aspect of their operations.
Frequently Asked Questions
What is the main goal of the BBG and CELLforCURE partnership?
The partnership aims to enhance the global manufacturing capabilities for Advanced Therapy Medicinal Products, bridging resources between the U.S. and Europe.
How does BBG Advanced Therapies support ATMP developers?
BBG Advanced Therapies provides comprehensive services including cell and tissue processing, testing, and clinical trial support, ensuring compliance with regulatory standards.
What makes CELLforCURE’s facilities unique?
CELLforCURE combines cutting-edge GMP-certified spaces with a strong commitment to quality control throughout the production process.
Why is the collaboration beneficial for patients?
The collaboration facilitates faster development of therapies and improved access, enabling more efficient multinational clinical trials and quicker patient access to innovative treatments.
How do these companies contribute to the field of regenerative medicine?
Both companies elevate the standard of care in regenerative medicine through advanced manufacturing capabilities, allowing for the development of innovative cell and gene therapies that save lives.
